| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
|
| [2] |
Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines[J]. Eur Urol 2021,79(1): 82-104.
|
| [3] |
Rouprêt M, Babjuk M, Burger M, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update[J]. Eur Urol, 2021, 79(1): 62-79.
|
| [4] |
Sylvester RJ, Rodríguez O, Hernández V, et al. European association of urology (eau) prognostic factor risk groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel[J]. Eur Urol, 2021,79(4): 480-488.
|
| [5] |
Gaisa NT, Tilki D, Losen I, et al. Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ[J]. Hum Pathol, 2008, 39(8):1258-1262.
|
| [6] |
Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma[J]. Am J Pathol, 2005, 166(5): 1533-1539.
|
| [7] |
Fujii T, Shimada K, Tatsumi Y, et al. Micro RNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1[J]. BMC Cancer, 2015, 15: 818.
|
| [8] |
程亮, 黄文斌, 陈杰. 膀胱小细胞癌临床病理学和分子遗传学研究进展[J]. 中华病理学杂志，2007, 36(10): 700-703.
|
| [9] |
Siddiqui EJ, Shabbir MA, Mikhailidis DP, et al. The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation[J]. BJU Int, 2006, 97(3): 634-639.
|
| [10] |
吴开杰. JAMA Oncol:对膀胱小细胞癌遗传谱的认识及其在诊断、治疗中的应用. 现代泌尿外科杂志[J]. 2018, 23(2): 143.
|
| [11] |
Wang Y, Li Q, Wang J, et al. Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up[J]. Med Oncol, 2019, 36(12): 98.
|
| [12] |
Shen P, Jing Y, Zhang R, et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics[J]. Oncogene, 2018, 37(22):3039-3044.
|
| [13] |
Bell RJ, Rube HT, Xavier-Magalhães A, et al. Understanding TERT promoter mutations: a common path to immortality[J]. Mol Cancer Res, 2016, 14(4): 315-323.
|
| [14] |
Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism[J]. Proc Natl Acad Sci USA, 2013, 110(43): 17426-17431.
|
| [15] |
Abbosh PH, Wang M, Eble JN, et al. Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder[J]. Mod Pathol, 2008, 21(3): 355-362.
|
| [16] |
Wang X, MacLennan GT, Lopez-Beltran A, et al. Small cell carcinoma of the urinary bladder-histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis[J]. Appl Immunohistochem Mol Morphol, 2007, 15(1): 8-18.
|
| [17] |
Puzyrenko A, Nomani L, Iczkowski K, et al. Small cell carcinoma of the urinary bladder: distinctive cytological characteristics and Cyto-histologic correlation[J]. Ann Diagn Pathol, 2022, 59: 151947.
|
| [18] |
Muranaka T, Hashimoto K, Shindo T, et al. Clinical characteristics and treatment outcomes of patients with small cell carcinoma of the urinary bladder[J]. Curr Urol, 2022, 16(3): 136-141.
|
| [19] |
田向永, 闫天中, 武小强, 等. 膀胱小细胞神经内分泌癌的研究进展[J]. 中华泌尿外科杂志, 2018, 39(4): 311-313.
|
| [20] |
Ali Nahit Şendur M, Aksoy S, Arık Z, et al. Small cell carcinoma of the urinary bladder with hypercalcemia[J]. Med Oncol, 2012, 29(2): 827-828.
|
| [21] |
谌丹丹, 魏新华, 杨蕊梦, 等. 膀胱神经内分泌肿瘤的CT表现[J]. 临床放射学杂志, 2020, 39(4): 736-740.
|
| [22] |
谌丹丹, 江新青, 杨蕊梦, 等. 不同病理级别膀胱神经内分泌肿瘤CT表现[J]. 中国医学影像技术, 2020, 36(8): 1207-1210.
|
| [23] |
Kim JC, Kim KH, Jung S. Small cell carcinoma of the urinary bladder: CT and MR imaging findings[J]. Korean J Radiol, 2003, 4(2): 130-135.
|
| [24] |
Engles CD, Slobodov G, Buethe DD, et al. Primary mixed neuroendocrine carcinoma of the bladder with large cell component: a case report and review of the literature[J]. Int Urol Nephrol, 2012, 44(4): 1021-1025.
|
| [25] |
Chau C, Frcr YR, PhD AC, et al. Treatment outcomes for small cell carcinoma of the bladder: results from a UK patient retrospective cohort study[J]. Int J Radiat Oncol Biol Phys, 2021, 110(4): 1143-1150.
|
| [26] |
李森, 刘晓强, 邹雲, 等. 原发性膀胱小细胞癌的诊治体会和预后分析[J]. 临床泌尿外科杂志, 2014, 29(7): 596-600.
|
| [27] |
谭智勇, 李宁, 师林伟, 等. 原发性膀胱小细胞癌1例报告[J]. 现代泌尿生殖肿瘤杂志, 2019, 11(1): 54-55.
|
| [28] |
Moretto P, Wood L, Emmenegger U, et al. Management of small cell carcinoma of the bladder: consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)[J]. Can Urol Assoc J, 2013, 7(1/2): E44-E56.
|
| [29] |
Naito A, Taguchi S, Nakagawa T, et al. Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder[J]. World J Urol, 2017, 35(1): 97-103.
|
| [30] |
Zheng X, Liu D, Fallon JT, et al. Distinct genetic alterations in small cell carcinoma from different anatomic sites[J]. Exp Hematol Oncol, 2015, 4: 2.
|
| [31] |
Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients[J]. Cancer, 2004, 101(5): 957-962.
|
| [32] |
杨涛, 谢弘, 傅强, 等. 泌尿系统神经内分泌癌的临床特征及诊治分析[J]. 中华泌尿外科杂志, 2020, 41(7): 507-511.
|
| [33] |
Oh J, Eigl B, Black PC, et al. Small cell carcinoma of the bladder: a population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy[J]. Can Urol Assoc J, 2022, 16(2): 55-62.
|
| [34] |
Siefker-Radtke AO, Dinney CP, Abrahams N A, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience[J]. J Urol, 2004, 172(2): 481-484.
|
| [35] |
Nejat RJ, Purohit R, Goluboff ET, et al. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy[J]. Urol Oncol, 2001, 6(2): 53-55.
|
| [36] |
Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology[J]. Cancer, 2017, 123(22): 4346-4355.
|
| [37] |
Stenehjem DD, Tran D, Nkrumah MA, et al. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer[J]. Onco Targets Ther, 2018, 11: 5973-5989.
|
| [38] |
Zhou TC, Sankin A I, Porcelli SA, et al. A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment[J]. Urol Oncol, 2017, 35(1): 14-20.
|
| [39] |
Wilde L, Ali SM, Solomides CC, et al. Response to pembrolizumab in a patient with chemotherapy refractory bladder cancer with small cell variant histology: a case report and review of the literature[J]. Clin Genitourin Cancer, 2017, 15(3): e521-e524.
|
| [40] |
Kim J, Kwiatkowski D, McConkey DJ, et al. The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability[J]. Eur Urol, 2019, 75(6): 961-964.
|
| [41] |
Koshkin VS, Garcia JA, Reynolds J, et al. Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target[J]. Clin Cancer Res, 2019, 25(1): 210-221.
|
| [42] |
Neşe N, Kumbaraci B S, Baydar D E, et al. Small cell carcinomas of the bladder highly express somatostatin receptor type 2A: impact on prognosis and treatment—a multicenter study of urooncology society, Turkey[J]. Appl Immunohistochem Mol Morphol, 2016, 24(4): 253-260.
|